Galera Therapeutics, Inc. financial data

Symbol
GRTX on OTC
Industry
Pharmaceutical Preparations
Location
45 Liberty Blvd., Suite 230, Malvern, PA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 368 % +6.38%
Debt-to-equity -119 % +19.9%
Return On Equity 22 % -67.4%
Return On Assets -116 % +16.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.4M shares +23.8%
Common Stock, Shares, Outstanding 54.4M shares +24.1%
Entity Public Float 130M USD +303%
Common Stock, Value, Issued 54K USD +22.7%
Weighted Average Number of Shares Outstanding, Basic 54.4M shares +26.7%
Weighted Average Number of Shares Outstanding, Diluted 54.4M shares +26.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.2M USD -60.8%
General and Administrative Expense 12.8M USD -50.1%
Operating Income (Loss) -27.4M USD +51.9%
Net Income (Loss) Attributable to Parent -29.1M USD +58.8%
Earnings Per Share, Basic -0.07 USD/shares +85.4%
Earnings Per Share, Diluted -0.07 USD/shares +85.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.7M USD -55.8%
Assets, Current 12M USD -71.5%
Property, Plant and Equipment, Net 56K USD -73.3%
Operating Lease, Right-of-Use Asset 1.14M USD -11.7%
Goodwill 881K USD 0%
Other Assets, Noncurrent 90K USD -94.5%
Assets 16.4M USD -66.1%
Accounts Payable, Current 812K USD -85.3%
Accrued Liabilities, Current 1.16M USD -85.5%
Liabilities, Current 2.13M USD -84.4%
Operating Lease, Liability, Noncurrent 1.04M USD -13.1%
Liabilities 154M USD -5.43%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -446M USD -6.98%
Stockholders' Equity Attributable to Parent -138M USD -20%
Liabilities and Equity 16.4M USD -66.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.79M USD +58.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 54.4M shares +24.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.79M USD -122%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.7M USD -55.9%
Deferred Tax Assets, Valuation Allowance 72.9M USD +24.7%
Deferred Tax Assets, Gross 73.7M USD +24.5%
Operating Lease, Liability 1.19M USD -9.61%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -29.1M USD +58.7%
Lessee, Operating Lease, Liability, to be Paid 1.4M USD -12.1%
Property, Plant and Equipment, Gross 530K USD -51.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 220K USD +1.38%
Lessee, Operating Lease, Liability, to be Paid, Year One 217K USD +11.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 207K USD -24.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 224K USD +1.82%
Deferred Tax Assets, Operating Loss Carryforwards 49M USD +17.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 633K USD -26.1%
Operating Lease, Payments 53K USD +20.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 9K USD -55%
Deferred Tax Assets, Net of Valuation Allowance 804K USD +10.6%
Share-based Payment Arrangement, Expense 4.18M USD -35.5%
Interest Expense 2.79M USD -81.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%